MET and neoplasm: In this study we have shown that MLD therapy is effective in PDX models having diverse EGFR inhibitor resistance mechanisms, including EGFR T790M mutation, KRAS mutation, MET amplification and even SCLC transformation, highlighting that MLD therapy could apply to a diverse range of EGFR TKI resistant tumours.